Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $73.00

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned a consensus recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $73.00.

A number of brokerages have issued reports on JSPR. Evercore ISI restated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada cut their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Tuesday, August 13th. Finally, BTIG Research initiated coverage on Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 price target on the stock.

Institutional Trading of Jasper Therapeutics

Several institutional investors have recently made changes to their positions in JSPR. Rhumbline Advisers purchased a new position in Jasper Therapeutics during the 2nd quarter valued at approximately $300,000. Virtu Financial LLC bought a new stake in Jasper Therapeutics during the 1st quarter valued at $306,000. American Century Companies Inc. raised its position in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $599,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Jasper Therapeutics in the 2nd quarter valued at $740,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $18.83 on Monday. The business’s 50 day simple moving average is $19.66 and its 200 day simple moving average is $22.50. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The stock has a market capitalization of $283.66 million, a PE ratio of -3.34 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. As a group, research analysts expect that Jasper Therapeutics will post -4.16 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.